Israel-based Adva Biotechnology Ltd. is temporarily blocked from marketing its new cell therapy device in the U.S., after a Maryland federal judge found the device likely infringes a rival’s patented technology.
Lonza Walkersville Inc. and Octane Biotech Inc. asked for a preliminary injunction after the companies said they learned Adva planned to debut its X3 bioreactor system at a trade show this week in Miami.
Judge Paula Xinis in the U.S. District Court for the District of Maryland granted the injunction in a Jan. 21 opinion.
Xinis said that after interpreting a disputed term, there was “no real dispute” ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.